Describe the safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia
and determine preliminary effectiveness and pharmacokinetics (PK) of sildenafil. Funding
Source - FDA OOPD.
Phase:
Phase 2
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborators:
Duke University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) The Emmes Company, LLC The EMMES Corporation